NAMPT与恶性肿瘤的进展

doi:10.11904/j.issn.1002-3070.2016.02.014

Abstract

Abstract: Nicotinamide phosphoribosyltransferase(NAMPT)is the rate-limiting enzyme that catalyzes the first step in Nicotinamide adenine dinucleotide(NAD)biosynthesis and regulates biological processes such as metabolism,growth and apoptosis of cells.In the past few years,a large number of studies have found that expression level of NAMPT is increased in a variety of malignancies,which is associated with the progression and treatment of malignant tumors.The research of the mechanism of NAMPT in malignant tumors and molecule inhibitors of the NAMPT have brought new hope and prospect for the treatment of malignant tumors.This article makes a brief review of NAMPT research status in malignant tumors.

Key words: NAMPT, Nalignant tumors, Progression, Treatment

CLC Number:

LI Guanghao, ZHANG Yubao. The research progress on NAMPT in malignant tumors[J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(2): 158-161.

References

1 Wang T,Zhang X,Bheda P,et al.Structure of Nampt/PBEF/visfatin,a mammalian NAD+ biosynthetic enzyme[J].Nat Struct Mol Biol,2006,13(7):661-662.
2 Sethi JK.Is PBEF/visfatin/Nampt an authentic adipokine relevant to the metabolic syndrome[J].Curr Hypertens Rep,2007,9(1):33-38.
3 Magni G,Amici A,Emanuelli M,et al.Enzymology of NAD+ homeostasis in man[J].Cell Mol Life Sci,2004,61(1):19-34.
4 Ramsey KM,Yoshino J,Brace CS,et al.Circadian clock feedback cycle through NAMPT-mediated NAD+ biosynthesis[J].Science,2009,324(5927):651-654.
5 Shackelford RE,Mayhall K,Maxwell NM,et al.Nicotinamide phosphoribosyltransferase in malignancy:a review[J].Genes Cancer,2013,4(11-12):447-456.
6 Garten A,Petzold S,Korner A,et al.Nampt:linking NAD biology,metabolism and cancer[J].Trends Endocrinol Metab,2009,20(3):130-138.
7 Bi TQ,Che XM.Nampt/PBEF/visfatin and cancer[J].Cancer Biol Ther,2010,10(2):119-125.
8 孙欢,张凯,艾文兵.Nampt 在胶质瘤中的研究进展[J].实用肿瘤学杂志,2014,28(1):89-92.
9 Galli U,Travelli C,Massarotti A,et al.Medicinal chemistry of nicotinamide phosphoribosyltransferase(NAMPT)inhibitors[J].J Med Chem,2013,56(16):6279-6296.
10 Wang X,Xu TY,Liu XZ,et al.Discovery of novel inhibitors and fluorescent probe targeting NAMPT[J].Sci Rep,2015,26(5):12657-12665.
11 Hong SM,Park CW,Kim SW,et al.NAMPT suppresses glucose deprivation-induced oxidative stress by increasing NADPH levels in breast cancer[J].Oncogene,2015,2015:415.
12 Park HJ,Kim SR,Kim SS,et al.Visfatin promotes cell and tumor growth by upregulating Notch1 in breast cancer[J].Oncotarget,2014,5(13):5087-5099.
13 Zhou T,Wang T,Garcia JG.Expression of nicotinamide phosphoribosyltransferase-influenced genes predicts recurrence-free survival in lung and breast cancers[J].Sci Rep,2014,39(4):6107-6115.
14 Yang H,Yang T,Baur JA,et al.Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival[J].Cell,2007,130(6):1095-1107.
15 Sharif T,Ahn DG,Liu RZ,et al.The NAD salvage pathway modulates cancer cell viability via p73[J].Cell Death Differ,2015,2015:134.
16 Wang B,Hasan MK,Alvarado E,et al.NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response[J].Oncogene,2011,30(8):907-921.
17 Patel ST,Mistry T,Brown JE,et al.A novel role for the adipokine visfatin/pre-B cell colony-enhancing factor 1 in prostate carcinogenesis[J].Peptides,2010,31(1):51-57.
18 Dan L,Klimenkova O,Klimiankou M,et al.The role of sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells[J].Haematologica,2012,97(4):551-559.
19 Audrito V,Serra S,Brusa D,et al.Extracellular nicotinamide phosphoribosyltransferase(NAMPT)promotes M2 macrophage polarization in chronic lymphocytic leukemia[J].Blood,2015,125(1):111-123.
20 Lv X,Zhang L,Zhu Y,et al.Regulative effect of Nampt on tumor progression and cell viability in human colorectal cancer[J].J Cancer,2015,6(9):849-858.
21 Neubauer K,Misa IB,Diakowska D,et al.Nampt/PBEF/visfatin upregulation in colorectal tumors,mirrored in normal tissue and whole blood of colorectal cancer patients,is associated with metastasis,hypoxia,IL1beta,and anemia[J].Biomed Res Int,2015,2015:523930.
22 Schuster S,Penke M,Gorski T,et al.Resveratrol differentially regulates NAMPT and SIRT1 in hepatocarcinoma cells and primary human hepatocytes[J].PLoS One,2014,9(3):e91045.
23 Garten A,Petzold S,Barnikol-Oettler A,et al.Nicotinamide phosphoribosyltransferase(NAMPT/PBEF/visfatin)is constitutively released from human hepatocytes[J].Biochem Biophys Res Commun,2010,391(1):376-381.
24 Bauer L,Venz S,Junker H,et al.Nicotinamide phosphoribosyltransferase and prostaglandin H2 synthase 2 are up-regulated in human pancreatic adenocarcinoma cells after stimulation with interleukin-1[J].Int J Oncol,2009,35(1):97-107.
25 Chini CC,Guerrico AM,Nin V,et al.Targeting of NAD metabolism in pancreatic cancer cells:potential novel therapy for pancreatic tumors[J].Clin Cancer Res,2014,20(1):120-130.
26 Sawicka-Gutaj N,Waligorska-Stachura J,Andrusiewicz M,et al.Nicotinamide phosphorybosiltransferase overexpression in thyroid malignancies and its correlation with tumor stage and with survivin/survivin DEx3 expression[J].Tumour Biol,2015,36(10):7859-7863.
27 Zhang K,Zhou B,Zhang P,et al.Genetic variants in NAMPT predict bladder cancer risk and prognosis in individuals from southwest Chinese Han group[J].Tumour Biol,2014,35(5):4031-4040.
28 Ke HL,Lin HH,Li WM,et al.High visfatin expression predicts poor prognosis of upper tract urothelial carcinoma patients[J].Am J Cancer Res,2015,5(8):2447-2454.
29 Zhao W,Chen R,Zhao M,et al.High glucose promotes gastric cancer chemoresistance in vivo and in vitro[J].Mol Med Rep,2015,12(1):843-850.
30 Zhang C,Yan D,Wang S,et al.Genetic polymorphisms of NAMPT related with susceptibility to esophageal squamous cell carcinoma[J].BMC Gastroenterol,2015,15:49.
31 Shackelford RE,Bui MM,Coppola D,et al.Over-expression of nicotinamide phosphoribosyltransferase in ovarian cancers[J].Int J Clin Exp Pathol,2010,3(5):522-527.
32 Garten A,Schuster S,Penke M,et al.Physiological and pathophysiological roles of NAMPT and NAD metabolism[J].Nat Rev Endocrinol,2015,11(9):535-546.
33 Zhang LQ,Heruth DP,Ye SQ.Nicotinamide phosphoribosyltransferase in human diseases[J].J Bioanal Biomed,2011,28(3):13-25.
34 Hasmann M,Schemainda I.FK866,a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase,represents a novel mechanism for induction of tumor cell apoptosis[J].Cancer Res,2003,63(21):7436-7442.
35 Grozio A,Sociali G,Sturla L,et al.CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells[J].J Biol Chem,2013,288(36):25938-25949.
36 Thakur BK,Dittrich T,Chandra P,et al.Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells[J].Int J Cancer,2013,132(4):766-774.
37 Von Heideman A,Berglund A,Larsson R,et al.Safety and efficacy of NAD depleting cancer drugs:results of a phase I clinical trial of CHS 828 and overview of published data[J].Cancer Chemother Pharmacol,2010,65(6):1165-1172.
38 Hjarnaa PJ,Jonsson E,Latini S,et al.CHS 828,a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo[J].Cancer Res,1999,59(22):5751-5757.
39 Olesen UH,Christensen MK,Bjorkling F,et al.Anticancer agent CHS-828 inhibits cellular synthesis of NAD[J].Biochem Biophys Res Commun,2008,367(4):799-804.
40 Chiarugi A,Dolle C,Felici R,et al.The NAD metabolome-a key determinant of cancer cell biology[J].Nat Rev Cancer,2012,12(11):741-752.
41 Johanson V,Arvidsson Y,Kolby L,et al.Antitumoural effects of the pyridyl cyanoguanidine CHS 828 on three different types of neuroendocrine tumours xenografted to nude mice[J].Neuroendocrinology,2005,82(3-4):171-176.
42 Kato H,Ito E,Shi W,et al.Efficacy of combining GMX1777 with radiation therapy for human head and neck carcinoma[J].Clin Cancer Res,2010,16(3):898-911.
43 Xiao Y,Elkins K,Durieux JK,et al.Dependence of tumor cell lines and patient-derived tumors on the NAD salvage pathway renders them sensitive to NAMPT inhibition with GNE-618[J].Neoplasia,2013,15(10):1151-1160.
44 Sampath D,Zabka TS,Misner DL,et al.Inhibition of nicotinamide phosphoribosyltransferase(NAMPT)as a therapeutic strategy in cancer[J].Pharmacol Ther,2015,151(6):16-31.
45 Wang W,Elkins K,Oh A,et al.Structural basis for resistance to diverse classes of NAMPT inhibitors[J].PLoS One,2014,9(10):e109366.
46 Shackelford RE,Mayhall K,Maxwell NM,et al.Nicotinamide phosphoribosyltransferase in malignancy:a review[J].Genes Cancer,2013,4(11-12):447-456.

[1]	LI Shan,ZHAO Chunbo,QIAO Wenbo. Progress in the application of intraoperative radiotherapy in pancreatic cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 280-283.
[2]	FANG Lin, LIU Chao, ZHANG Chunhui, ZHANG Yanqiao. Research status and treatment strategies of maintenance therapy for metastatic colorectal cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 173-178.
[3]	XING Zhichao, MAI Wei. Research progress on potential targets of liposarcoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 82-86.
[4]	TIAN Yang, WU Huaxing. Clinical application of ultra-fine nasal endoscopy in digestive tract stenosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 550-554.
[5]	WANG Yuan, SUN Yihua. Advance in the role of β-catenin in soft tissue tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 455-459.
[6]	ZHANG Li,FANG Kewei,YUE Xi,WANG Hong,YANG Hanfeng,XU Xiaoxue. Research progress of cryoablation for bone metastases [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 353-356.
[7]	LI Lin, LI Zhigao. The relationship between metformin and different molecular subtypes of breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 267-270.
[8]	HAN Xuejiao, LI Yanchun, SUN lichun, LU Hailing. Research progress of the relationship between 14-3-3ζ and malignant tumor [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 543-547.
[9]	JIANG Ying, LIU Baogang. Research progress of RCAN1 in malignant tumor [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 559-563.
[10]	WANG Shuo, SONG Yanni. Advances in pathogenesis of breast Paget's disease [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(5): 444-447.
[11]	GU Xiuying,GU Xiaofen,ZHU Junyu,ZHOU Tianhong,ZHU Lin. Analysis of lung cancer screening results of 9265 urban residents in Urumqi from year 2014 to 2016 [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(3): 242-245.
[12]	LI Rudong, HOU Jiachen, CUI Xiaohan, WANG Xvdong. Progress in diagnosis and treatment of stomach hepatoid adenocaecinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(1): 53-56.
[13]	FAN Mingxv, ZHAO Yanbin, LI Boyang, WANG Yan. Research progress in the Notch pathway in malignant tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(1): 57-60.
[14]	LIN Qianhuang, XU Hui, HUAN Jinliang. Research progress in diagnosis and treatment of papillary thyroid microcarcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(1): 61-64.
[15]	DONG Lei,LIU Qing,JIANG Renbing. Analysis of clinical diagnosis,treatment and prognosis of epithelioid sarcoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(6): 511-515.

The research progress on NAMPT in malignant tumors

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments